Literature DB >> 1548775

Inhibition of human immunodeficiency virus type 1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev.

S Kubota1, R Furuta, M Maki, M Hatanaka.   

Abstract

A nonfunctional mutant of human immunodeficiency virus type 1 Rev was created by deleting seven amino acid residues within the nucleolar targeting signal. This mutant Rev remained in the cytoplasm in expressed cells and strongly inhibited the function of Rev by interfering with the nuclear/nucleolar localization of coexpressed Rev. These findings strongly suggest the multimerization of Rev in the cytoplasm before migration to the nucleus/nucleolus, where wild-type Rev functions as a trans-regulator.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548775      PMCID: PMC289048     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif.

Authors:  M L Zapp; T J Hope; T G Parslow; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

2.  Functional similarity of HIV-I rev and HTLV-I rex proteins: identification of a new nucleolar-targeting signal in rev protein.

Authors:  S Kubota; H Siomi; T Satoh; S Endo; M Maki; M Hatanaka
Journal:  Biochem Biophys Res Commun       Date:  1989-08-15       Impact factor: 3.575

3.  Expression of a provirus of human T cell leukaemia virus type I by DNA transfection.

Authors:  K Mori; H Sabe; H Siomi; T Iino; A Tanaka; K Takeuchi; K Hirayoshi; M Hatanaka
Journal:  J Gen Virol       Date:  1987-02       Impact factor: 3.891

4.  The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization.

Authors:  M Emerman; R Vazeux; K Peden
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

5.  The art gene product of human immunodeficiency virus is required for replication.

Authors:  E Terwilliger; R Burghoff; R Sia; J Sodroski; W Haseltine; C Rosen
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

6.  Expression of functional acetylcholine receptor from cloned cDNAs.

Authors:  M Mishina; T Kurosaki; T Tobimatsu; Y Morimoto; M Noda; T Yamamoto; M Terao; J Lindstrom; T Takahashi; M Kuno
Journal:  Nature       Date:  1984 Feb 16-22       Impact factor: 49.962

7.  Transdominant human T-cell lymphotropic virus type I TAX1 mutant that fails to localize to the nucleus.

Authors:  S D Gitlin; P F Lindholm; S J Marriott; J N Brady
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

8.  A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization.

Authors:  S Endo; S Kubota; H Siomi; A Adachi; S Oroszlan; M Maki; M Hatanaka
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

View more
  12 in total

1.  Over-expression of the HIV-1 Rev promotes death of nondividing eukaryotic cells.

Authors:  Aviad Levin; Zvi Hayouka; Assaf Friedler; Abraham Loyter
Journal:  Virus Genes       Date:  2010-02-12       Impact factor: 2.332

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 3.  A defective HIV-1 vector for gene transfer to human lymphocytes.

Authors:  C Parolin; J Sodroski
Journal:  J Mol Med (Berl)       Date:  1995-06       Impact factor: 4.599

4.  Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein.

Authors:  S Kubota; L Duan; R A Furuta; M Hatanaka; R J Pomerantz
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Exchange of the basic domain of human immunodeficiency virus type 1 Rev for a polyarginine stretch expands the RNA binding specificity, and a minimal arginine cluster is required for optimal RRE RNA binding affinity, nuclear accumulation, and trans-activation.

Authors:  Y S Nam; A Petrovic; K S Jeong; S Venkatesan
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins.

Authors:  C Ulich; D Harrich; P Estes; R B Gaynor
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Diminished rev-mediated stimulation of human immunodeficiency virus type 1 protein synthesis is a hallmark of human astrocytes.

Authors:  E Ludwig; F C Silberstein; J van Empel; V Erfle; M Neumann; R Brack-Werner
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Occurrence and role of an early antigen and evidence for transforming ability of porcine circovirus.

Authors:  I Tischer; D Peters; S Pociuli
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy.

Authors:  R A Furuta; S Kubota; M Maki; Y Miyazaki; T Hattori; M Hatanaka
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function.

Authors:  M Neumann; B K Felber; A Kleinschmidt; B Froese; V Erfle; G N Pavlakis; R Brack-Werner
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.